4.7 Review

Potential of antibody-drug conjugates (ADCs) for cancer therapy

Related references

Note: Only part of the references are listed.
Review Immunology

Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies

Brian A. Baldo

Summary: Identification of new disease-associated biomarkers and the use of monoclonal antibodies (mAbs) has led to improved treatment outcomes and successful new biological treatments for previously neglected diseases. However, mAbs can also cause adverse reactions and hypersensitivities.

ANTIBODIES (2022)

Review Oncology

Unlocking the potential of antibody-drug conjugates for cancer therapy

Joshua Z. Drago et al.

Summary: Nine ADCs are currently approved for cancer treatment, with many more in development. Advances in synthetic biochemistry have led to a new generation of ADCs promising improved tissue specificity and cytotoxicity. Despite impressive activity against treatment-refractory cancers, challenges such as systemic toxicity and acquired resistance remain. This review discusses the design, mechanism of action, and limitations of ADCs, proposing strategies to maximize their therapeutic benefit for cancer patients.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Article Pharmacology & Pharmacy

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency

Dian Su et al.

Summary: The design of linkers plays a crucial role in modulating the stability and payload release efficiency of ADCs, thus impacting their pharmacokinetics, efficacy, and toxicity. Integrated strategies can help achieve a balance in linker design to optimize desired efficacy.

FRONTIERS IN PHARMACOLOGY (2021)

Article Immunology

Introduction to Antibody-Drug Conjugates

Mark C. Pettinato

Summary: ADCs are innovative biopharmaceutical products that combine monoclonal antibodies with small molecule drugs, primarily used in cancer treatment but with potential for other diseases. There are currently ten FDA-approved ADCs and over 90 in clinical development worldwide. The field has made significant advances in antibody discovery and formulation, but also faces challenges and requires continued innovation for future developments.

ANTIBODIES (2021)

Review Biochemistry & Molecular Biology

Protease-activated prodrugs: strategies, challenges, and future directions

Marcin Poreba

FEBS JOURNAL (2020)

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Oncology

Targeting apoptosis in cancer therapy

Benedito A. Carneiro et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Chemistry, Medicinal

Nature-derived anticancer steroids outside cardica glycosides

Jiaqi Xiao et al.

FITOTERAPIA (2020)

Review Chemistry, Medicinal

Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment

Chunlin Zhuang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)

Review Oncology

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

Michael J. Birrer et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Article Medicine, General & Internal

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Biotechnology & Applied Microbiology

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy

Jeffrey C. Kang et al.

NATURE BIOTECHNOLOGY (2019)

Review Multidisciplinary Sciences

A view on drug resistance in cancer

Neil Vasan et al.

NATURE (2019)

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Review Cell Biology

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Kyoji Tsuchikama et al.

PROTEIN & CELL (2018)

Review Biotechnology & Applied Microbiology

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Paul J. Carter et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

Article Biochemical Research Methods

Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification

Dian Su et al.

BIOCONJUGATE CHEMISTRY (2018)

Review Oncology

Fate of Antibody-Drug Conjugates in Cancer Cells

Cecile Chalouni et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)

Article Multidisciplinary Sciences

Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice

Yasuaki Anami et al.

NATURE COMMUNICATIONS (2018)

Review Oncology

Targeted radionuclide therapy in combined-modality regimens

Martin R. Gill et al.

LANCET ONCOLOGY (2017)

Review Biotechnology & Applied Microbiology

Strategies and challenges for the next generation of antibody drug conjugates

Alain Beck et al.

NATURE REVIEWS DRUG DISCOVERY (2017)

Review Chemistry, Medicinal

Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates

Muhammad Kalim et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2017)

Review Oncology

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

Alexander H. Staudacher et al.

BRITISH JOURNAL OF CANCER (2017)

Review Chemistry, Multidisciplinary

Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis

Erika A. Crane et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)

Article Pharmacology & Pharmacy

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

Hans-Peter Gerber et al.

BIOCHEMICAL PHARMACOLOGY (2016)

Review Oncology

Antibody-drug conjugates-an emerging class of cancer treatment

Nikolaos Diamantis et al.

BRITISH JOURNAL OF CANCER (2016)

Editorial Material Immunology

Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

Janine Schuurman et al.

CURRENT OPINION IN IMMUNOLOGY (2016)

Review Biochemistry & Molecular Biology

Linkers Having a Crucial Role in Antibody-Drug Conjugates

Jun Lu et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)

Article Pharmacology & Pharmacy

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates

Aman P. Singh et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)

Article Chemistry, Multidisciplinary

Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates

Jeffrey C. Kern et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)

Editorial Material Chemistry, Medicinal

Expanding the Reach of Antibody-Drug Conjugates

Ravi V. J. Chari

ACS MEDICINAL CHEMISTRY LETTERS (2016)

Article Multidisciplinary Sciences

Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics

Andrew B. Waight et al.

PLOS ONE (2016)

Review Biochemistry & Molecular Biology

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics

Eunhee G. Kim et al.

BIOMOLECULES & THERAPEUTICS (2015)

Review Biochemistry & Molecular Biology

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

Christina Peters et al.

BIOSCIENCE REPORTS (2015)

Review Pharmacology & Pharmacy

Emerging formats for next-generation antibody drug conjugates

Mahendra P. Deonarain et al.

EXPERT OPINION ON DRUG DISCOVERY (2015)

Review Biochemistry & Molecular Biology

Mechanisms of action of therapeutic antibodies for cancer

J. M. Redman et al.

MOLECULAR IMMUNOLOGY (2015)

Article Medicine, Research & Experimental

Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates

Andreas Maderna et al.

MOLECULAR PHARMACEUTICS (2015)

Article Medicine, Research & Experimental

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985

Ronald C. Elgersma et al.

MOLECULAR PHARMACEUTICS (2015)

Review Chemistry, Multidisciplinary

Current ADC Linker Chemistry

Nareshkumar Jain et al.

PHARMACEUTICAL RESEARCH (2015)

Review Pharmacology & Pharmacy

Antibody-drug conjugates: current status and future directions

Heidi L. Perez et al.

DRUG DISCOVERY TODAY (2014)

Review Medicine, Research & Experimental

Site-specific antibody drug conjugates for cancer therapy

Siler Panowski et al.

Review Immunology

IgG subclasses and allotypes: from structure to effector functions

Gestur Vidarsson et al.

FRONTIERS IN IMMUNOLOGY (2014)

Review Medicine, Research & Experimental

Antibody-Drug Conjugates in Cancer Therapy

Eric L. Sievers et al.

ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)

Article Pharmacology & Pharmacy

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

Oktay Tacar et al.

JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)

Article Oncology

Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers

Serengulam V. Govindan et al.

MOLECULAR CANCER THERAPEUTICS (2013)

News Item Biotechnology & Applied Microbiology

Maturing antibody-drug conjugate pipeline hits 30

Asher Mullard

NATURE REVIEWS DRUG DISCOVERY (2013)

Review Immunology

Antibody Drug Conjugates as Cancer Therapeutics

Pamela A. Trail

ANTIBODIES (2013)

Article Biology

A mechanistic compartmental model for total antibody uptake in tumors

Greg M. Thurber et al.

JOURNAL OF THEORETICAL BIOLOGY (2012)

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Oncology

Antibody Conjugate Therapeutics: Challenges and Potential

Beverly A. Teicher et al.

CLINICAL CANCER RESEARCH (2011)

Review Pharmacology & Pharmacy

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

Mohammad Tabrizi et al.

AAPS JOURNAL (2010)

Article Oncology

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

Yelena V. Kovtun et al.

CANCER RESEARCH (2010)

Review Biochemistry & Molecular Biology

Antibody-drug conjugates: targeted drug delivery for cancer

Stephen C. Alley et al.

CURRENT OPINION IN CHEMICAL BIOLOGY (2010)

Review Immunology

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Louis M. Weiner et al.

NATURE REVIEWS IMMUNOLOGY (2010)

Review Chemistry, Multidisciplinary

Targeted cancer therapy: Conferring specificity to cytotoxic drugs

Ravi V. J. Chari

ACCOUNTS OF CHEMICAL RESEARCH (2008)

Review Oncology

Antibody-drug conjugates for cancer therapy

Paul J. Carter et al.

CANCER JOURNAL (2008)

Review Oncology

Paul Ehrlich's magic bullet concept: 100 years of progress

Klaus Strebhardt et al.

NATURE REVIEWS CANCER (2008)

Article Oncology

Cell killing by antibody-drug conjugates

Yelena V. Kovtun et al.

CANCER LETTERS (2007)

Article Oncology

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer

Maurizio Scaltriti et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)

Review Biochemistry & Molecular Biology

Monoclonal antibody therapy

D O'Mahony et al.

FRONTIERS IN BIOSCIENCE-LANDMARK (2006)

Article Environmental Sciences

The bystander effect

EJ Hall

HEALTH PHYSICS (2003)

Review Multidisciplinary Sciences

Regulated portals of entry into the cell

SD Conner et al.

NATURE (2003)